ACE2 and COVID-19: Furthermore, taking into account the RAAS axis and inflammation, RAAS inhibitors increase ACE2 expression, and angiotensin II receptor blockers (ARBs) inhibit Ang II AT1R interactions, and COVID-19 patients may benefit from a combination of RAAS inhibitors, ARBs, and statins [14].